Two FDA Clearances in Less Than a Month Have Top Analysts Watching Xtant Medical (XTNT)
Investors and financial analysis firms have taken note of two paramount FDA approvals for Xtant Medical (NYSE: XTNT) within less than a month’s time. The supplier of spine surgery and orthopedic products announced on November 17 that it won FDA clearance for its Irix-C cervical cage, as covered by a recent article (http://nnw.fm/Omu1Z). Xtant Medical stated that the product was previously only cleared for use with autogenous bone graft, but is now cleared for use with autografts or allografts, as well as an expanded range of levels allowable (now from C3-T1 to C2-T1). This news was immediately followed by the…